1. Generics Bulletin
  2. >>Products

Generics Firms On Standby With Tecfidera Appeal Due ‘At Any Time’

Implication Of Potential Pro-Biogen Ruling Unclear

 
• By Dean Rudge

Biogen feels a decision on its appeal over Tecfidera is due any day now, but management was cautious over the potential to scrub the market of generics following market formation last year.

Biogen_Switzerland
first-quarter 2021 sales of Tecfidera nosedived by 79% • Source: Shutterstock

A decision on Biogen’s appeal against a US district court ruling that opened the floodgates for generic competition to the originator’s Tecfidera (dimethyl fumarate) blockbuster “could really come at any time now,” management says, after Biogen reported an 80% drop in Tecfidera sales in the first quarter of this year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.